 |
human donor hematopoietic stem and progenitor cells (HSPC) that have been treated ex vivo with TBX-4000 |
|---|---|
| Trade Name | |
| Orphan Indication | Enhancement of cell engraftment in patients receiving hematopoietic stem cell transplant |
| USA Market Approval | USA |
| USA Designation Date | 2016-06-02 00:00:00 |
| Sponsor | Taiga Biotechnologies, Inc.;12635 Montview Boulevard, Fitzsimmons BBioscience Park Center;Aurora, Colorado, 80045 |
